Menu Search
Equities

TFF Pharmaceuticals Inc

0K30:MUN

TFF Pharmaceuticals Inc

Actions
  • Price (EUR)2.18
  • Today's Change0.00 / 0.00%
  • Shares traded500.00
  • 1 Year change-58.08%
  • Beta--
Data delayed at least 15 minutes, as of Oct 31 2024 07:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.

  • Revenue in USD (TTM)1.20m
  • Net income in USD-19.39m
  • Incorporated2018
  • Employees19.00
  • Location
    TFF Pharmaceuticals Inc2600 Via Fortuna Ste 360AUSTIN 78746-7983United StatesUSA
  • Fax+1 (302) 655-5049
  • Websitehttps://tffpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.